Hereditary Cancer IVF Screening in Hong Kong | Hong Kong PGT-M Embryo Genetic Testing Process

AI Summary

Hereditary cancer patients undergoing IVF screening in Hong Kong refers to the use of Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) technology to screen embryos for specific pathogenic genes during in vitro fertilization. Embryos not carrying the hereditary tumor pathogenic gene are selected for transfer, thereby blocking the transmission of hereditary cancer to offspring. Hong Kong has an early start in the PGT-M field, clear regulations, and laboratory standards aligned with international norms, making it a chosen destination for fertility intervention for carriers of various hereditary tumor syndromes.

1. Core Answer: How IVF Screening in Hong Kong Blocks Hereditary Cancer

PGT-M (Preimplantation Genetic Testing for Monogenic disorders) is currently the most mature embryo screening technology for monogenic genetic diseases. For hereditary tumors, the process can be summarized as:

• Confirm the Pathogenic Gene — First, identify the pathogenic mutation site in the family (e.g., BRCA1 c.68_69delAG) through genetic counseling and testing.
• IVF to Form Embryos — Obtain eggs through ovarian stimulation, fertilize with sperm in vitro to form blastocysts.
• Embryo Biopsy — Take 5 to 10 trophectoderm cells from the blastocyst stage for genetic analysis.
• Genetic Testing — Use NGS or PCR technology to detect whether the embryo carries the pathogenic mutation.
• Select for Transfer — Choose blastocysts not carrying the pathogenic gene for frozen embryo transfer.

This technology does not screen all cancer genes; it only targets known, specific familial pathogenic sites. Therefore, not everyone with a "family history of cancer" is suitable; a genetic diagnosis must be completed first.

2. Why PGT-M Screening is Necessary

Approximately 5% to 10% of malignant tumors have a clear genetic predisposition caused by a single pathogenic gene mutation, following an autosomal dominant inheritance pattern. Offspring of carriers have a 50% chance of inheriting the mutation, often with earlier onset and significantly increased risk of malignancy.

Compared to prenatal diagnosis (amniocentesis), the advantage of PGT-M is completing the screening before embryo transfer, avoiding the dilemma of terminating a pregnancy if a pathogenic gene is detected. For families with a history of multiple pregnancy failures or ethical concerns, this is a more proactive solution.

3. Suitable Candidates

Not everyone with a "family history of cancer" is suitable for PGT-M. The following groups are clearly indicated:

• Confirmed carriers of a pathogenic gene mutation — Identified through genetic testing for clear pathogenic sites such as BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, TP53, APC, RET, etc.
• Clear family history of hereditary tumor syndrome — Meeting clinical diagnostic criteria for Hereditary Breast-Ovarian Cancer Syndrome, Lynch Syndrome, Familial Adenomatous Polyposis, Li-Fraumeni Syndrome, etc.
• Have reproductive needs — And wish to avoid passing the pathogenic gene to the next generation through embryo selection.
• One or both partners are carriers of the pathogenic gene — And are of appropriate age with ovarian reserve sufficient for an IVF cycle.

For families without a clearly identified pathogenic gene, genetic counseling and testing must be completed first to find the mutation site before entering the PGT-M process. Some families may not be suitable for PGT-M if the mutation site is unclear or involves a polygenic complex inheritance pattern.

4. Professional Medical Perspective

From the clinical perspective of reproductive medicine and genetic counseling, using PGT-M for hereditary tumor blockade requires three prerequisites:

• Clear genotype-phenotype relationship — Sufficient evidence-based evidence links the gene mutation to cancer risk, with high penetrance.
• Mutation site can be accurately detected — Including point mutations, small deletions/insertions, etc., requiring the laboratory to have corresponding detection capabilities.
• Clear family inheritance pattern — Usually autosomal dominant inheritance, confirmed through family studies.

Reproductive centers in Hong Kong commonly use a dual verification strategy of Next-Generation Sequencing (NGS) + Linkage Analysis for PGT-M, achieving a detection accuracy of > 99%. Doctors often recommend simultaneous PGT-A (Preimplantation Genetic Testing for Aneuploidy), as embryo chromosomal abnormalities are a major cause of transfer failure and miscarriage, and this does not conflict with gene mutation screening.

The role of the genetic counselor is equally crucial — informing patients about the limitations of PGT-M before testing (e.g., undetected mutation sites, mosaic embryos, risk of test failure) and interpreting results afterward to help patients make informed decisions.

5. Differences Between Hong Kong and Mainland China

For PGT-M, Hong Kong and Mainland China differ in technology application, regulatory oversight, and testing scope, directly impacting patient choice.

Hong Kong's advantages lie in mature regulations, broad gene coverage, and the ability to perform simultaneous chromosomal screening, making it suitable for those seeking comprehensive technology, rare family mutations, or sensitivity to ethical approval times. Mainland China offers lower costs and convenient transportation, but may face testing capacity limitations for rare genes or complex families.

6. Most Easily Overlooked Details

In practice, several aspects are often overlooked but directly affect whether screening proceeds smoothly:

• Proband sample is indispensable — PGT-M requires a known pathogenic mutation site, typically using the genetic report of an affected family member (proband) as a reference. If the proband has passed away or samples cannot be obtained, testing difficulty and cost increase significantly.
• Genetic counseling is not a one-time event — Hong Kong requires at least two genetic counseling sessions before PGT-M: one before genetic testing (informed consent, risk assessment) and one after results (report interpretation, transfer strategy formulation).
• Timing of embryo biopsy — Biopsy is performed at the blastocyst stage on days 5 to 6. Not all embryos develop to a biopsiable stage; approximately 60% to 80% of fertilized eggs form blastocysts.
• Storage period for frozen embryos — Hong Kong has regulations on embryo cryopreservation, typically 5 to 10 years. Check the center's storage policy in advance.
• Carrier partner also needs screening — Even if the partner has no family history, carrier screening is recommended to rule out superimposed risks of recessive genetic diseases.

7. Common Pitfalls

• "Having a family history of cancer qualifies for PGT-M" — Incorrect. A clear pathogenic gene mutation must be identified, with sufficient causal evidence linking the mutation to the disease. If only "multiple family members have cancer" without genetic testing, proband testing or family whole exome sequencing is needed, which may take 3 to 6 months.
• "PGT-M can screen all cancer genes" — Incorrect. PGT-M only targets known, specific pathogenic sites, not the entire genome. It cannot prevent polygenic complex inheritance or de novo mutations.
• "PGT-M guarantees the child will not get cancer" — Inaccurate. PGT-M only blocks the specific hereditary cancer risk of that family and cannot reduce cancer probability from other factors (environment, de novo mutations, other genes).
• "Choosing Hong Kong means no need for genetic counseling" — Incorrect. Hong Kong has stricter genetic counseling requirements for PGT-M than Mainland China, which must be completed by a registered genetic counselor or clinical geneticist.
• "The cost is just the IVF cost" — Overlooks PGT-M testing fees, embryo freezing fees, biopsy fees, and possible embryo transport fees (if cross-center testing is needed). Total cost is usually HKD 100,000 to 150,000 higher than standard IVF.

8. Actual Process and Timeline

A complete PGT-M cycle from initial consultation to transfer typically takes 3 to 6 months, divided into the following stages:

During the entire cycle, the gene confirmation stage is most prone to delays. If the proband sample is unavailable or the family mutation is unclear, an additional 2 to 3 months may be needed for linkage analysis. It is recommended to prepare all medical records and genetic test reports in advance and complete genetic counseling via remote consultation before traveling to Hong Kong to save time.

Cost Influencing Factors

The total cost of PGT-M in Hong Kong mainly consists of the following components:

• Genetic Counseling and Genetic Testing: Approximately HKD 20,000 to 50,000 (including family verification, linkage analysis).
• Ovarian Stimulation Medications: Approximately HKD 20,000 to 40,000 (varies by protocol and medication duration).
• Egg Retrieval Surgery and IVF Laboratory: Approximately HKD 50,000 to 60,000.
• Embryo Biopsy + PGT-M Testing: Approximately HKD 60,000 to 100,000 (based on number of genes and embryos tested).
• Simultaneous PGT-A Testing: Approximately HKD 15,000 to 25,000.
• Embryo Freezing and Storage: Approximately HKD 6,000 to 12,000 per year.
• Frozen Embryo Transfer Cycle: Approximately HKD 20,000 to 40,000.

Fee structures vary significantly between reproductive centers. It is advisable to request a detailed fee schedule during the initial consultation, clarifying whether medications, biopsy, testing, and transfer fees are included, to avoid additional charges later.

9. Frequently Asked Questions

9.1 What materials need to be prepared?

• Genetic test report of the proband (if available)
• Family cancer history records (at least three-generation pedigree)
• Identification documents, marriage certificate, passport (valid for at least 6 months) for both partners
• Records of previous fertility history, miscarriage history, surgical history
• Infectious disease screening reports (Hepatitis B, Hepatitis C, HIV, Syphilis, etc.)

9.2 Can I do only PGT-M without PGT-A?

Technically yes, but doctors usually recommend doing both simultaneously. Embryo chromosomal aneuploidy is the primary cause of transfer failure and miscarriage, and it occurs independently of gene mutations. If only PGT-M is performed without PGT-A, a "mutation-free" embryo transferred may still fail to implant or miscarry due to chromosomal abnormalities, potentially prolonging the overall timeline.

9.3 How long do test results take?

Testing on the NGS platform typically takes 4 to 6 weeks. If linkage analysis or family verification is also performed, it may extend to 6 to 8 weeks. The frozen embryo transfer cycle usually starts after menstruation, aligning with the release of test results.

9.4 Does age significantly affect success rates?

Age directly impacts egg quality and the rate of chromosomally normal embryos. Women under 35 have a higher probability of obtaining transferable embryos. After age 40, both egg quantity and quality decline, potentially requiring multiple ovarian stimulation cycles to obtain enough embryos for testing. However, PGT-M testing itself is not affected by age; as long as embryos form and can be biopsied, the accuracy remains consistent.

9.5 Which Hong Kong hospital has extensive experience with PGT-M?

Queen Mary Hospital (HKU), Hong Kong Sanatorium & Hospital, Union Hospital, and the Hong Kong Reproductive Medicine Centre all have extensive experience with PGT-M. Each center's strengths in gene panels and testing procedures vary slightly. It is advisable to choose a center with validated data for your specific pathogenic gene type, rather than relying solely on reputation.

This content is compiled and edited from reproductive medicine knowledge, based on the current guidelines of the Hong Kong Council on Human Reproductive Technology (HTA) and industry consensus as of 2025. Please refer to the advice of your attending physician for specific diagnosis and treatment plans.